Tracking the tail
Immune-checkpoint inhibitors have deeply changed the therapeutic landscape of advanced non-small cell lung cancer without actionable genomic alterations. Immune-checkpoint inhibitors have become standard front-line therapy, especially among patients with tumours expressing high levels of programmed...
Saved in:
| Main Authors: | Alex Friedlaender, Alfredo Addeo, Stephen V Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000971.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
by: Alex Friedlaender, et al.
Published: (2020-05-01) -
The Changing Landscape of Urothelial Carcinoma Therapy: Updates from ASCO GU 2023
by: Alex Friedlaender
Published: (2023-06-01) -
Parting gravity’s tail: quadrupole tails at fifth order and beyond via integer partitions
by: Alex Edison
Published: (2025-02-01) -
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
by: Alfredo Addeo
Published: (2022-06-01) -
Emerging Treatment Options in Lung Cancer
by: Alfredo Addeo
Published: (2022-10-01)